Related Concept Videos
Electroconvulsive Therapy
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: MAOIs and Other Agents
Parenteral Anesthetics: Overview
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Drug Therapy
Antianxiety Medications
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Chest Radiograph Interpretation: Online Teaching Resources for Non-Radiologists.
Related Experiment Video
Updated: Jan 5, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Ketamine and Treatment-Resistant Depression.
Jennifer K Lent1, Albert Arredondo2, Marilyn A Pugh3
1is the chief nurse anesthetist at Yukon Kuskokwim Delta Regional Hospital in Bethel, Alaska. The author was a student in the Doctor of Nurse Anesthesia Practice program at Texas Wesleyan University in Fort Worth, Texas, at the time this article was written.
Subanesthetic ketamine infusions show promise for treatment-resistant depression, significantly reducing symptoms short-term. Further research is needed to confirm long-term efficacy and safety, including optimal dosing for ketamine therapy.
More Related Videos
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Major depressive disorder impacts millions, with a significant portion experiencing treatment resistance.
- Limited effective options exist for treatment-resistant depression beyond electroconvulsive therapy and transcranial magnetic stimulation.
Purpose of the Study:
- To examine the efficacy of subanesthetic ketamine infusions for treating patients with treatment-resistant depression.
- To synthesize current evidence on ketamine's antidepressant effects and tolerability.
Main Methods:
- Systematic review of 10 randomized controlled trials and systematic reviews.
- Analysis of short-term and long-term efficacy data.
- Assessment of ketamine infusion tolerability and adverse effects.
Main Results:
- Evidence suggests ketamine significantly decreases depression severity at short-term assessments.
- Long-term efficacy data for ketamine treatment is currently lacking.
- Ketamine infusion therapy was generally well-tolerated with minimal adverse effects.
Conclusions:
- Ketamine infusions represent a promising avenue for treatment-resistant depression.
- Further large-scale randomized controlled trials are necessary to establish long-term efficacy, safety, and optimal dosing protocols.
- Understanding the dependence profile of ketamine is crucial for clinical application.

